Mounir Ait‐Khaled

3.4k total citations
54 papers, 1.5k citations indexed

About

Mounir Ait‐Khaled is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Mounir Ait‐Khaled has authored 54 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Infectious Diseases, 41 papers in Virology and 11 papers in Epidemiology. Recurrent topics in Mounir Ait‐Khaled's work include HIV/AIDS drug development and treatment (46 papers), HIV Research and Treatment (41 papers) and HIV/AIDS Research and Interventions (27 papers). Mounir Ait‐Khaled is often cited by papers focused on HIV/AIDS drug development and treatment (46 papers), HIV Research and Treatment (41 papers) and HIV/AIDS Research and Interventions (27 papers). Mounir Ait‐Khaled collaborates with scholars based in United Kingdom, United States and France. Mounir Ait‐Khaled's co-authors include Vincent C. Emery, Margaret Tisdale, Christopher Stone, Paul Griffiths, Michael Kidd, Duncan A. Clark, Amy Cutrell, Philip Griffin, Brian Wynne and Christine Katlama and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Mounir Ait‐Khaled

50 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mounir Ait‐Khaled United Kingdom	21	1.2k	991	486	267	180	54	1.5k
Mark Oette Germany	20	591 0.5×	524 0.5×	269 0.6×	120 0.4×	156 0.9×	66	1.1k
Silvia Nozza Italy	19	679 0.6×	724 0.7×	469 1.0×	284 1.1×	76 0.4×	148	1.3k
Sidonie Lambert-Niclot France	21	1.1k 0.9×	1.1k 1.1×	241 0.5×	185 0.7×	74 0.4×	63	1.4k
Bruno You France	9	579 0.5×	329 0.3×	311 0.6×	98 0.4×	39 0.2×	15	832
Jayvant Heera United States	18	700 0.6×	771 0.8×	254 0.5×	124 0.5×	39 0.2×	43	992
Alain Lafeuillade France	24	1.1k 0.9×	1.2k 1.2×	368 0.8×	280 1.0×	52 0.3×	89	1.7k
J Lange Netherlands	15	623 0.5×	672 0.7×	250 0.5×	96 0.4×	42 0.2×	23	910
Pauline Campa France	16	592 0.5×	637 0.6×	274 0.6×	91 0.3×	26 0.1×	28	914
Marie Gueudin France	18	633 0.5×	523 0.5×	469 1.0×	25 0.1×	57 0.3×	39	982
Jane Yeo United Kingdom	13	493 0.4×	350 0.4×	330 0.7×	177 0.7×	48 0.3×	13	768

Countries citing papers authored by Mounir Ait‐Khaled

Since Specialization

Citations

This map shows the geographic impact of Mounir Ait‐Khaled's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mounir Ait‐Khaled with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mounir Ait‐Khaled more than expected).

Fields of papers citing papers by Mounir Ait‐Khaled

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mounir Ait‐Khaled. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mounir Ait‐Khaled. The network helps show where Mounir Ait‐Khaled may publish in the future.

Co-authorship network of co-authors of Mounir Ait‐Khaled

This figure shows the co-authorship network connecting the top 25 collaborators of Mounir Ait‐Khaled. A scholar is included among the top collaborators of Mounir Ait‐Khaled based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mounir Ait‐Khaled. Mounir Ait‐Khaled is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ait‐Khaled, Mounir, et al.. (2024). Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study. Open Forum Infectious Diseases. 11(5). ofae227–ofae227.

Chandasana, Hardik, Rajendra Singh, Kimberly K. Adkison, Mounir Ait‐Khaled, & Teodora Pene Dumitrescu. (2024). Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1. Antimicrobial Agents and Chemotherapy. 68(5). e0150423–e0150423. 1 indexed citations

Chandasana, Hardik, M. Bush, Cindy Vavro, et al.. (2024). Integrated Population Exposure–Response of Dolutegravir in HIV‐1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics. Clinical Pharmacology & Therapeutics. 116(4). 1100–1109.

Batterham, Rachel L., Núria Espinosa, Christine Katlama, et al.. (2023). Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens. Open Forum Infectious Diseases. 10(7). ofad359–ofad359. 6 indexed citations

Wang, Ruolan, Jonathan Wright, Mounir Ait‐Khaled, et al.. (2023). Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144. Viruses. 15(6). 1350–1350. 1 indexed citations

Wit, Stéphane De, Agathe Rami, Fabrice Bonnet, et al.. (2022). 1584. CARISEL A Hybrid III Implementation Effectiveness Study of implementation of Cabotegravir plus Rilpivirine Long Acting (CAB+RPV LA) in EU Health Care Settings Key Clinical and Implementation Outcomes by Implementation Arm. Open Forum Infectious Diseases. 9(Supplement_2). 9 indexed citations

Wyk, Jean van, F. Ajana, Fiona Bisshop, et al.. (2021). Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study). HIV Medicine. 22. 28–28.

Ait‐Khaled, Mounir, Juan Sierra Madero, Vicente Estrada, et al.. (2021). Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies. SHILAP Revista de lepidopterología. 23(1). 9–14. 6 indexed citations

Molina, Jean‐Michel, Mounir Ait‐Khaled, Rita Rinaldi, et al.. (2009). Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. Journal of Antimicrobial Chemotherapy. 64(2). 398–410. 8 indexed citations

10.

Marcelin, Anne‐Geneviève, Philippe Flandre, Jean‐Michel Molina, et al.. (2008). Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials. Antimicrobial Agents and Chemotherapy. 52(12). 4251–4257. 8 indexed citations

11.

Givens, Naomi, Christopher Stone, Philip Griffin, et al.. (2004). Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens. HIV Medicine. 5(6). 394–399. 30 indexed citations

12.

Ait‐Khaled, Mounir, Christopher Stone, Bonaventura Clotet, et al.. (2002). M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS. 16(12). 1686–1689. 41 indexed citations

13.

Pillay, Deenan, A Sarah Walker, Diana M. Gibb, et al.. (2002). Impact of Human Immunodeficiency Virus Type 1 Subtypes on Virologic Response and Emergence of Drug Resistance among Children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. The Journal of Infectious Diseases. 186(5). 617–625. 68 indexed citations

14.

Miller, Veronica, Mounir Ait‐Khaled, Christopher Stone, et al.. (2000). HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS. 14(2). 163–171. 107 indexed citations

15.

Ait‐Khaled, Mounir, et al.. (1999). A Novel Genotype Encoding a Single Amino Acid Insertion and Five Other Substitutions Between Residues 64 and 74 of the HIV-1 Reverse Transcriptase Confers High-Level Cross-Resistance to Nucleoside Reverse Transcriptase Inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes. 22(2). 139–139. 19 indexed citations

16.

Griffiths, Paul, Mounir Ait‐Khaled, C P Bearcroft, et al.. (1999). Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. Journal of Medical Virology. 59(4). 496–501. 122 indexed citations

17.

Clarke, John R., Mounir Ait‐Khaled, A. Colin Wright, et al.. (1999). Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. Journal of Medical Virology. 59(3). 364–368. 34 indexed citations

18.

Kidd, Michael, Duncan A. Clark, Mounir Ait‐Khaled, Paul Griffiths, & Vincent C. Emery. (1996). Measurement of Human Herpesvirus 7 Load in Peripheral Blood and Saliva of Healthy Subjects by Quantitative Polymerase Chain Reaction. The Journal of Infectious Diseases. 174(2). 396–401. 70 indexed citations

19.

Ait‐Khaled, Mounir, James E. McLaughlin, Margaret Johnson, & Vincent C. Emery. (1995). Distinct HIV-1 long terminal repeat quasispecies present in nervous tissues compared to that in lung, blood and lymphoid tissues of an AIDS patient. AIDS. 9(7). 675–684. 61 indexed citations

20.

Ait‐Khaled, Mounir & Vincent C. Emery. (1994). Phylogenetic relationship between human immunodeficiency virus type 1 (HIV-1) long terminal repeat natural variants present in the lymph node and peripheral blood of three HIV-1-infected individuals. Journal of General Virology. 75(7). 1615–1621. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact